FDG-PET in Follicular Lymphoma Management | Zendy

Caroline BodetMilin | Zendy; T. Eugène | Zendy; Thomas Gastinne | Zendy; Éric Frampas | Zendy; Steven Le Gouill | Zendy; Françoise KraeberBodéré | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

FDG-PET in Follicular Lymphoma Management

Author(s) -

Caroline BodetMilin,

T. Eugène,

Thomas Gastinne,

Éric Frampas,

Steven Le Gouill,

Françoise KraeberBodéré

Publication year - 2012

Publication title -

journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.228

H-Index - 54

eISSN - 1687-8469

pISSN - 1687-8450

DOI - 10.1155/2012/370272

Subject(s) - medicine , follicular lymphoma , positron emission tomography , lymphoma , radiology , pet ct , nuclear medicine , positron emission tomography computed tomography , pathology

18-Fluoro-deoxyglucose positron emission tomography/computerised tomography (FDG PET/CT) is commonly used in the management of patients with lymphomas and is recommended for both initial staging and response assessment after treatment in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. Despite the FDG avidity of follicular lymphoma (FL), FDG PET/CT is not yet applied in standard clinical practice for patients with FL. However, FDG PET/CT is more accurate than conventional imaging for initial staging, often prompting significant management change, and allows noninvasive characterization to guide assessment of high-grade transformation. For restaging, FDG PET/CT assists in distinguishing between scar tissue and viable tumors in residual masses and a positive PET after induction treatment would seem to predict a shorter progression-free survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research